EDAP TMS S.A. - ADR
NASDAQ:EDAP 10:01:54 AM EDT
Products, Regulatory
EDAP Announces Positive Results From Phase 2 Study For Therapeutic High-Intensity Focused Ultrasound
Published: 01/31/2023 13:50 GMT
EDAP TMS S.A. - ADR (EDAP) - Edap Announces Positive Results From Phase 2 Study Evaluating Therapeutic High-intensity Focused Ultrasound (hifu) for the Treatment of Rectal Endometriosis.
Edap Tms Sa - Focal One Hifu Treatment Resulted in Significant Improvements in Endometriosis Symptoms and Quality of Life.
Edap Tms Sa - Positive Safety Profile With 96.7% of Patients With No Or Non-significant Adverse Events.
Edap Tms Sa - Intends to Initiate Randomized, Double-blind, Sham-controlled Study in 2q 2023.
Edap Tms Sa - Focal One Hifu Treatment Resulted in Significant Improvements in Endometriosis Symptoms and Quality of Life.
Edap Tms Sa - Positive Safety Profile With 96.7% of Patients With No Or Non-significant Adverse Events.
Edap Tms Sa - Intends to Initiate Randomized, Double-blind, Sham-controlled Study in 2q 2023.